Viking Therapeutics Posts Q3 Loss -$1.55 vs. FactSet Estimate of -$1.06
Viking Therapeutics reported a Q3 loss of -$1.55, compared with FactSet’s estimate of -$1.06.
Related stories
Deepak Nitrite Q2 Profit More Than Triples to ₹398 Crore
Net profit rose to ₹398 crore from ₹118.7 crore a year earlier. Revenue increased 61.7% year on year to ₹3,076 crore from ₹1,901.9 crore.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC
Garware Technical Fibres Q2 Net Profit Rises 83.4% to ₹58.6 Crore
Net profit for the second quarter of FY27 rose 83.4% year on year to ₹58.6 crore, while revenue increased 33% to ₹462.6 crore.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC
Suryoday SFB Q2 Net Profit More Than Doubles to ₹77 Crore
Suryoday Small Finance Bank reported net profit of ₹77 crore in the second quarter, compared with ₹30 crore a year earlier. Net interest income rose 43% year on year.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC
Mastercard Reports Third-Quarter 2026 Revenue of $9.81 Billion
Net revenue rose 14% year over year to $9.81 billion. Net income increased 17.9% to $4.63 billion, and diluted EPS rose 21.7% to $5.28.
M impact | EQUITY | Oct 29, 2026, 02:21 PM UTC
FTAI Aviation Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 02:21 PM UTC
Howmet Executive Says F-35 Spare-Parts Demand Remains Healthy
A Howmet executive said demand for F-35 fighter jet spares remains healthy as the aircraft fleet expands.
M impact | EQUITY | Oct 29, 2026, 02:21 PM UTC